FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081386294> ?p ?o ?g. }

• W3081386294 endingPage "778" @default.
• W3081386294 startingPage "770" @default.
• W3081386294 abstract "BackgroundThe anti-progesterone drug mifepristone and the prostaglandin misoprostol can be used to treat missed miscarriage. However, it is unclear whether a combination of mifepristone and misoprostol is more effective than administering misoprostol alone. We investigated whether treatment with mifepristone plus misoprostol would result in a higher rate of completion of missed miscarriage compared with misoprostol alone.MethodsMifeMiso was a multicentre, double-blind, placebo-controlled, randomised trial in 28 UK hospitals. Women were eligible for enrolment if they were aged 16 years and older, diagnosed with a missed miscarriage by pelvic ultrasound scan in the first 14 weeks of pregnancy, chose to have medical management of miscarriage, and were willing and able to give informed consent. Participants were randomly assigned (1:1) to a single dose of oral mifepristone 200 mg or an oral placebo tablet, both followed by a single dose of vaginal, oral, or sublingual misoprostol 800 μg 2 days later. Randomisation was managed via a secure web-based randomisation program, with minimisation to balance study group assignments according to maternal age (<30 years vs ≥30 years), body-mass index (<35 kg/m2 vs ≥35 kg/m2), previous parity (nulliparous women vs parous women), gestational age (<70 days vs ≥70 days), amount of bleeding (Pictorial Blood Assessment Chart score; ≤2 vs ≥3), and randomising centre. Participants, clinicians, pharmacists, trial nurses, and midwives were masked to study group assignment throughout the trial. The primary outcome was failure to spontaneously pass the gestational sac within 7 days after random assignment. Primary analyses were done according to intention-to-treat principles. The trial is registered with the ISRCTN registry, ISRCTN17405024.FindingsBetween Oct 3, 2017, and July 22, 2019, 2595 women were identified as being eligible for the MifeMiso trial. 711 women were randomly assigned to receive either mifepristone and misoprostol (357 women) or placebo and misoprostol (354 women). 696 (98%) of 711 women had available data for the primary outcome. 59 (17%) of 348 women in the mifepristone plus misoprostol group did not pass the gestational sac spontaneously within 7 days versus 82 (24%) of 348 women in the placebo plus misoprostol group (risk ratio [RR] 0·73, 95% CI 0·54–0·99; p=0·043). 62 (17%) of 355 women in the mifepristone plus misoprostol group required surgical intervention to complete the miscarriage versus 87 (25%) of 353 women in the placebo plus misoprostol group (0·71, 0·53–0·95; p=0·021). We found no difference in incidence of adverse events between the study groups.InterpretationTreatment with mifepristone plus misoprostol was more effective than misoprostol alone in the management of missed miscarriage. Women with missed miscarriage should be offered mifepristone pretreatment before misoprostol to increase the chance of successful miscarriage management, while reducing the need for miscarriage surgery.FundingUK National Institute for Health Research Health Technology Assessment Programme." @default.
• W3081386294 created "2020-09-01" @default.
• W3081386294 creator A5002078868 @default.
• W3081386294 creator A5003693687 @default.
• W3081386294 creator A5004965789 @default.
• W3081386294 creator A5006615531 @default.
• W3081386294 creator A5006661478 @default.
• W3081386294 creator A5008357548 @default.
• W3081386294 creator A5008499634 @default.
• W3081386294 creator A5009709576 @default.
• W3081386294 creator A5009892854 @default.
• W3081386294 creator A5011467466 @default.
• W3081386294 creator A5014462883 @default.
• W3081386294 creator A5019036180 @default.
• W3081386294 creator A5022179386 @default.
• W3081386294 creator A5024423524 @default.
• W3081386294 creator A5025282582 @default.
• W3081386294 creator A5025320338 @default.
• W3081386294 creator A5029342829 @default.
• W3081386294 creator A5030898100 @default.
• W3081386294 creator A5032102822 @default.
• W3081386294 creator A5033096415 @default.
• W3081386294 creator A5034013469 @default.
• W3081386294 creator A5034746747 @default.
• W3081386294 creator A5037040746 @default.
• W3081386294 creator A5037416404 @default.
• W3081386294 creator A5040739363 @default.
• W3081386294 creator A5043238593 @default.
• W3081386294 creator A5044327449 @default.
• W3081386294 creator A5044556308 @default.
• W3081386294 creator A5050088253 @default.
• W3081386294 creator A5052069259 @default.
• W3081386294 creator A5052868708 @default.
• W3081386294 creator A5065959964 @default.
• W3081386294 creator A5072400539 @default.
• W3081386294 creator A5073126414 @default.
• W3081386294 creator A5074505620 @default.
• W3081386294 creator A5081619599 @default.
• W3081386294 creator A5085303209 @default.
• W3081386294 creator A5085346363 @default.
• W3081386294 creator A5087495070 @default.
• W3081386294 creator A5088746943 @default.
• W3081386294 date "2020-09-01" @default.
• W3081386294 modified "2023-10-17" @default.
• W3081386294 title "Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial" @default.
• W3081386294 cites W1558095504 @default.
• W3081386294 cites W1652065838 @default.
• W3081386294 cites W1846596448 @default.
• W3081386294 cites W1969733684 @default.
• W3081386294 cites W1971622241 @default.
• W3081386294 cites W2013256551 @default.
• W3081386294 cites W2016096381 @default.
• W3081386294 cites W2030050870 @default.
• W3081386294 cites W2077672824 @default.
• W3081386294 cites W2087332138 @default.
• W3081386294 cites W2089301027 @default.
• W3081386294 cites W2098931866 @default.
• W3081386294 cites W2137542469 @default.
• W3081386294 cites W2142662718 @default.
• W3081386294 cites W2147452156 @default.
• W3081386294 cites W2163114814 @default.
• W3081386294 cites W2607039050 @default.
• W3081386294 cites W2806325823 @default.
• W3081386294 cites W2994658429 @default.
• W3081386294 cites W2998859040 @default.
• W3081386294 cites W4211196564 @default.
• W3081386294 cites W4239309506 @default.
• W3081386294 cites W4256066788 @default.
• W3081386294 cites W4362203754 @default.
• W3081386294 doi "https://doi.org/10.1016/s0140-6736(20)31788-8" @default.
• W3081386294 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7493715" @default.
• W3081386294 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32853559" @default.
• W3081386294 hasPublicationYear "2020" @default.
• W3081386294 type Work @default.
• W3081386294 sameAs 3081386294 @default.
• W3081386294 citedByCount "50" @default.
• W3081386294 countsByYear W30813862942020 @default.
• W3081386294 countsByYear W30813862942021 @default.
• W3081386294 countsByYear W30813862942022 @default.
• W3081386294 countsByYear W30813862942023 @default.
• W3081386294 crossrefType "journal-article" @default.
• W3081386294 hasAuthorship W3081386294A5002078868 @default.
• W3081386294 hasAuthorship W3081386294A5003693687 @default.
• W3081386294 hasAuthorship W3081386294A5004965789 @default.
• W3081386294 hasAuthorship W3081386294A5006615531 @default.
• W3081386294 hasAuthorship W3081386294A5006661478 @default.
• W3081386294 hasAuthorship W3081386294A5008357548 @default.
• W3081386294 hasAuthorship W3081386294A5008499634 @default.
• W3081386294 hasAuthorship W3081386294A5009709576 @default.
• W3081386294 hasAuthorship W3081386294A5009892854 @default.
• W3081386294 hasAuthorship W3081386294A5011467466 @default.
• W3081386294 hasAuthorship W3081386294A5014462883 @default.
• W3081386294 hasAuthorship W3081386294A5019036180 @default.
• W3081386294 hasAuthorship W3081386294A5022179386 @default.
• W3081386294 hasAuthorship W3081386294A5024423524 @default.
• W3081386294 hasAuthorship W3081386294A5025282582 @default.
• W3081386294 hasAuthorship W3081386294A5025320338 @default.
• W3081386294 hasAuthorship W3081386294A5029342829 @default.

• next